BioinksBioprintingLegislationStandards

Humabiologics GMP hydrogels are now ISO 13485 certified

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

The Humabiologics human-derived hydrogels for regenerative medicine are now ISO 13485:2016 certified as well as GMP compliant for the manufacturing of human-derived biomaterials. The scope of the certificate covers the design, manufacture, and distribution of human biomaterials, components, and sub-assemblies for use in research and development, medical devices, pharmaceuticals, and biologic products.

The ISO 13485:2016 registration positions Humabiologics among the first global providers of GMP (Good Manufacturing Practices) grade human-derived biomaterials to support and expedite the future development of human regenerative therapies and tissue models for drug discovery through clinically relevant high-quality products.

Humabiologics GMP hydrogels are now ISO 13485 certified Humabiologics is a regenerative medicine company founded by scientists and tissue industry experts focused on narrowing the gap between the gift of donated human tissues and researchers by providing human-derived biomaterials. The company develops and commercializes high-quality, affordable human-derived biomaterials for translational regenerative medicine applications such as cell therapy, bioprinting, tissue & disease modeling, and drug screening.

Recently, Humabiologics introduced the world’s first native human collagen and gelatin-based bioinks. By becoming ISO 13485:2016 registered, Humabiologics has proven its ability to manufacture these biomaterial hydrogels under strict regulatory conditions including those required under the FDA’s Good Manufacturing Practices (GMP).

“We are excited to continue our mission of providing clinically-relevant human-derived biomaterials under our GMP compliant ISO 13485 registered quality system to support our customers and partners for the development of regenerative human therapies and drug discovery”, said Dr. Mohammad Albanna, CEO & Founder of Humabiologics.“

As the field is accelerating towards creating human organs and tissues and paving the way to eliminate the use of unreliable animal models for drug discovery, we remain focused on consistently providing high-quality products to standardize these research endeavors around the world and reduce the time and cost that is needed to develop innovative personalized human therapies.

Research
Consumer Products AM 2024

This new market study from VoxelMatters provides an in-depth analysis and forecast of polymer and metal AM in the consumer products industry across the three core segments of the additive manufactu...

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Save
Accept all Services

Newsletter

Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.